Media Newsroom of

INEX Innovations Exchange


Established in 2006, Innovations Exchange Pte Ltd (INEX) is a pioneering molecular diagnostic company focused on the research, development, marketing and licensing of innovative technology for the advancement of women’s and fetal health. A spin out from the National University of Singapore (“NUS”), INEX collaborates with prominent clinicians, clinician-scientists and academic institutions to develop innovative technologies and revolutionise medicine for women’s healthcare. For more information, please visit

OvaCis™ is an innovative colourimetric kit that accurately discriminates benign from malignant epithelial ovarian cysts with 98% accuracy, in 5 minutes. More than 90% of all ovarian malignancies are of epithelial origin, called epithelial ovarian cancer (EOC). Ovarian cysts are commonly present in most EOCs. Each year a large number of women go for ovarian cystectomy to remove ovarian cysts that are thought to benign. The intraoperative detection of malignancy for women going for ovarian cystectomy is critical for triage of patients for the most suitable surgical procedures, particularly important for young patients who wish to preserve fertility, and prevent unnecessary multiple surgeries. For more information, please visit

INEX Announces Launch of World's First CE-IVD Point-of-Care Diagnostic Assay for the Detection of Ova

INEX Innovations Exchange Pte Ltd, a leading Women's Health Molecular Diagnostics Services Provider in Singapore, announced today that the OvaCis™ Assay is now CE marked for in vitro diagnostic use. It has been certified to meet the EC Directive 98/79/EC…


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login